Fibrin Degradation Products

Fibrin Degradation Products (FDPs) are fragments produced when plasmin breaks down fibrin and fibrinogen during fibrinolysis. Their presence in blood reflects activation of coagulation followed by fibrinolysis.

1. Indicator of Intravascular Coagulation & Fibrinolysis

Elevated FDPs indicate excessive clot formation and breakdown.

Commonly seen in disseminated intravascular coagulation (DIC), where widespread clotting consumes coagulation factors.

2. Diagnostic & Monitoring Value

DIC: Markedly increased FDPs support the diagnosis and help monitor response to therapy.

Thromboembolic disorders: Raised FDPs suggest recent or ongoing clot breakdown.

Post-thrombolytic therapy: Levels rise after treatment (e.g., with tPA), indicating effective fibrinolysis.

3. Association with Specific Clinical Conditions

Elevated FDPs are seen in:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Acute myocardial infarction
• Severe infections and sepsis
• Malignancy
• Obstetric complications (e.g., placental abruption, amniotic fluid embolism)
• Major trauma, surgery, burns

4. Effect on Hemostasis (Bleeding Tendency)

High FDP levels have anticoagulant effects:

• Inhibit fibrin polymerization
• Interfere with platelet aggregation
• Prolong thrombin time

➡️ This contributes to bleeding complications, especially in DIC.

5. Relationship to D-Dimer

D-dimer is a specific FDP derived only from cross-linked fibrin.

FDPs can arise from fibrinogen or fibrin, so they are less specific than D-dimer.

FDPs are useful when assessing global fibrinolytic activity, whereas D-dimer is preferred for ruling out VTE.

6. Prognostic Significance

Persistently high FDPs often indicate poor prognosis in:

• DIC
• Severe sepsis
• Advanced malignancy